Cargando…

Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution

PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for patients with non–small-cell lung cancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. METHODS: Between 2007 and 2015, 102 consecutive lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Abreu, Carlos E.C.V., Moraes, Fabio Y., Miranda, Fabiana A., Siqueira, Gabriela S.M., Gadia, Rafael, Haddad, Cecilia K., Carvalho, Heloisa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223518/
https://www.ncbi.nlm.nih.gov/pubmed/30085881
http://dx.doi.org/10.1200/JGO.18.00020
_version_ 1783369422401961984
author Abreu, Carlos E.C.V.
Moraes, Fabio Y.
Miranda, Fabiana A.
Siqueira, Gabriela S.M.
Gadia, Rafael
Haddad, Cecilia K.
Carvalho, Heloisa A.
author_facet Abreu, Carlos E.C.V.
Moraes, Fabio Y.
Miranda, Fabiana A.
Siqueira, Gabriela S.M.
Gadia, Rafael
Haddad, Cecilia K.
Carvalho, Heloisa A.
author_sort Abreu, Carlos E.C.V.
collection PubMed
description PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for patients with non–small-cell lung cancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. METHODS: Between 2007 and 2015, 102 consecutive lung lesions were treated with SBRT at our center, of which 59 primary NSCLC lesions (from 54 patients with inoperable disease) were retrospectively reviewed (43 lesions were excluded because of metastases or because there was no biopsy specimen). We report infield local control (LC) per SBRT target, regional or distant failure-free survival, and overall survival (OS) per patient, using Kaplan-Meier estimates. Serious toxicity was retrospectively scored using Common Terminology Criteria for Adverse Events, version 4. RESULTS: Most of the 54 patients were men (n = 41; 76%), median age was 75 years; stage IA (n = 36; 66%) and adenocarcinoma (n = 43; 80%) were the most common stage and histologic diagnosis, respectively. Five patients had two lung lesions. A median of three fractions (range, 3 to 5 fractions) and a total median dose of 54 Gy (range, 45 to 60 Gy) per lesion were prescribed. The median follow-up was 17.8 months (range, 4 to 56.4 months). The 2-year rates of LC, regional or distant failure-free survival, and OS were 89.1% (95% CI, 72.2% to 96%), 79% (95% CI, 59.8% to 89.8%), and 80% (95% CI, 64% to 89.8%), respectively. Grade 3 to 4 toxicities were observed in two patients (3%): grade 3 pneumonitis (n = 1) and grade 4 skin toxicity (n = 1). CONCLUSION: SBRT results in high rates of 2-year LC, regional or distant failure-free survival, and OS with low rates of severe toxicity in patients with inoperable primary NSCLC disease.
format Online
Article
Text
id pubmed-6223518
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-62235182018-11-13 Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution Abreu, Carlos E.C.V. Moraes, Fabio Y. Miranda, Fabiana A. Siqueira, Gabriela S.M. Gadia, Rafael Haddad, Cecilia K. Carvalho, Heloisa A. J Glob Oncol Original Report PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for patients with non–small-cell lung cancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. METHODS: Between 2007 and 2015, 102 consecutive lung lesions were treated with SBRT at our center, of which 59 primary NSCLC lesions (from 54 patients with inoperable disease) were retrospectively reviewed (43 lesions were excluded because of metastases or because there was no biopsy specimen). We report infield local control (LC) per SBRT target, regional or distant failure-free survival, and overall survival (OS) per patient, using Kaplan-Meier estimates. Serious toxicity was retrospectively scored using Common Terminology Criteria for Adverse Events, version 4. RESULTS: Most of the 54 patients were men (n = 41; 76%), median age was 75 years; stage IA (n = 36; 66%) and adenocarcinoma (n = 43; 80%) were the most common stage and histologic diagnosis, respectively. Five patients had two lung lesions. A median of three fractions (range, 3 to 5 fractions) and a total median dose of 54 Gy (range, 45 to 60 Gy) per lesion were prescribed. The median follow-up was 17.8 months (range, 4 to 56.4 months). The 2-year rates of LC, regional or distant failure-free survival, and OS were 89.1% (95% CI, 72.2% to 96%), 79% (95% CI, 59.8% to 89.8%), and 80% (95% CI, 64% to 89.8%), respectively. Grade 3 to 4 toxicities were observed in two patients (3%): grade 3 pneumonitis (n = 1) and grade 4 skin toxicity (n = 1). CONCLUSION: SBRT results in high rates of 2-year LC, regional or distant failure-free survival, and OS with low rates of severe toxicity in patients with inoperable primary NSCLC disease. American Society of Clinical Oncology 2018-07-26 /pmc/articles/PMC6223518/ /pubmed/30085881 http://dx.doi.org/10.1200/JGO.18.00020 Text en © 2018 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Original Report
Abreu, Carlos E.C.V.
Moraes, Fabio Y.
Miranda, Fabiana A.
Siqueira, Gabriela S.M.
Gadia, Rafael
Haddad, Cecilia K.
Carvalho, Heloisa A.
Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution
title Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution
title_full Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution
title_fullStr Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution
title_full_unstemmed Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution
title_short Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non–Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution
title_sort stereotactic body radiation therapy for biopsy-proven primary non–small-cell lung cancer: experience of patients with inoperable cancer at a single brazilian institution
topic Original Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223518/
https://www.ncbi.nlm.nih.gov/pubmed/30085881
http://dx.doi.org/10.1200/JGO.18.00020
work_keys_str_mv AT abreucarlosecv stereotacticbodyradiationtherapyforbiopsyprovenprimarynonsmallcelllungcancerexperienceofpatientswithinoperablecanceratasinglebrazilianinstitution
AT moraesfabioy stereotacticbodyradiationtherapyforbiopsyprovenprimarynonsmallcelllungcancerexperienceofpatientswithinoperablecanceratasinglebrazilianinstitution
AT mirandafabianaa stereotacticbodyradiationtherapyforbiopsyprovenprimarynonsmallcelllungcancerexperienceofpatientswithinoperablecanceratasinglebrazilianinstitution
AT siqueiragabrielasm stereotacticbodyradiationtherapyforbiopsyprovenprimarynonsmallcelllungcancerexperienceofpatientswithinoperablecanceratasinglebrazilianinstitution
AT gadiarafael stereotacticbodyradiationtherapyforbiopsyprovenprimarynonsmallcelllungcancerexperienceofpatientswithinoperablecanceratasinglebrazilianinstitution
AT haddadceciliak stereotacticbodyradiationtherapyforbiopsyprovenprimarynonsmallcelllungcancerexperienceofpatientswithinoperablecanceratasinglebrazilianinstitution
AT carvalhoheloisaa stereotacticbodyradiationtherapyforbiopsyprovenprimarynonsmallcelllungcancerexperienceofpatientswithinoperablecanceratasinglebrazilianinstitution